Several clinical trials are being set up to establish whether a drug RG1662 produced by Hoffman- La Roche Ltd. can improve neurocognitive function in people with Down Syndrome. This study is a Phase One clinical trial meaning the primary goals is to assess the safety of the drug. The effectiveness of the drug will also be assessed. The study is recruiting adults with Down Syndrome between the ages of 18 to 30. At present there are study centers set up in the US and UK.
For more on this clinical trial and the trial criteria, please go to: